# A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

> **NCT06705140** · PHASE3 · TERMINATED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 947 (actual)

## Conditions studied

- RSV Immunisation

## Interventions

- **BIOLOGICAL:** Low Dose (LD) RSVt vaccine
- **BIOLOGICAL:** Standard Dose (SD) RSVt vaccine
- **BIOLOGICAL:** High Dose (HD) RSVt vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06705140
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-25
- **Primary completion:** 2025-06-11
- **Final completion:** 2025-06-11
- **Target enrollment:** 947 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705140, "A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06705140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*